| Literature DB >> 35740214 |
Oluwasola Stephen Ayosanmi1, Babatunde Yusuf Alli2, Oluwatosin Adetolani Akingbule3, Adeyemi Hakeem Alaga4, Jason Perepelkin1, Delbaere Marjorie1, Sujit S Sansgiry5, Jeffrey Taylor1.
Abstract
It has been suggested that the COVID-19 pandemic led to an increase in self-medication practices across the world. Yet, there is no up-to-date synthesized evidence on the prevalence of self-medication that is attributable to the pandemic. This study aimed to conduct a systematic literature review on the prevalence and correlates of self-medication for the prevention and treatment of COVID-19 globally. The review was registered with the PROSPERO database. Searches were conducted following PRISMA guidelines, and relevant articles published between 1 April 2020 and 31 March 2022 were included. Pooled prevalence rate was conducted using the Meta package in R. A total of 14 studies from 14 countries, which represented 15,154 participants, were included. The prevalence of COVID-19-related self-medication ranged from 3.4-96%. The pooled prevalence of self-medication for this purpose was 44.9% (95% CI: 23.8%, 68.1%). Medications reported by studies for self-medication were antibiotics (79%), vitamins (64%), antimalarials (50%), herbal and natural products (50%), analgesics and antipyretics (43%), minerals and supplements (43%), cold and allergy preparations (29%), corticosteroids (14%), and antivirals (7%). The prevalence of self-medication with antibiotics is concerning. More public health education about responsible self-medication amidst the COVID-19 pandemic and future pandemics is required to mitigate the rising threat of antimicrobial resistance.Entities:
Keywords: COVID-19; home remedies; non-prescription drugs; pandemic; self-medication
Year: 2022 PMID: 35740214 PMCID: PMC9220378 DOI: 10.3390/antibiotics11060808
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1PRISMA flow diagram for the systematic literature review.
Assessment of the risk of bias in the reviewed studies.
| Assessment Parameters | Zhang, 2021 | Wegbom, 2021 | Quispe-Cañari, 2020 | Sadio, 2021 | Elayeh, 2021 | Shakeel, 2021 | Azhar, 2021 | Annette d’arqom, 2021 | de los Ángeles, 2020 | Heshmatifar, 2021 | Gaviria-Mendoza, 2022 | Okoye et al., 2022 | Dehghan, 2022 | Kristoffersen, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| 1. Were the aims/objectives of the study clear? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
|
| ||||||||||||||
| 2. Was the study design appropriate for the stated aim(s)? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 3. Was the sample size justified? | No | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 4. Was the target/reference population clearly defined? (Is it clear who the research was about?) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 5. Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes |
| 6. Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation? | Yes | No | No | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
| 7. Were measures undertaken to address and categorize non-responders? | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| 8. Were the risk factor and outcome variables measured appropriate to the aims of the study? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 9. Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published previously? | Yes | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 10. Is it clear what was used to determine statistical significance and/or precision estimates? (e.g., | Yes | Yes | Yes | Yes | Yes | ND | Yes | Yes | Yes | ND | Yes | Yes | Yes | Yes |
| 11. Were the methods (including statistical methods) sufficiently described to enable them to be repeated? | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes |
|
| ||||||||||||||
| 12. Were the basic data adequately described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 13. Did the response rate not raise concerns about non-response bias? | Yes | Yes | Yes | Yes | ND | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 14. If appropriate, was information about non-responders described? | No | No | No | No | No | No | No | No | No | No | No | No | No | No |
| 15. Were the results internally consistent? | ND | Yes | Yes | ND | ND | ND | ND | Yes | ND | ND | ND | ND | ND | ND |
| 16. Were the results for the analyses, as described in the methods, presented? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
|
| ||||||||||||||
| 17. Were the authors’ discussions and conclusions justified by the results? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 18. Were the limitations of the study discussed? | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
|
| ||||||||||||||
| 19. Was there information about any funding sources or conflicts of interest that may affect the authors’ interpretation of the results? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 20. Was ethical approval or consent of participants attained? | Yes | Yes | Yes | Yes | Yes | Yes | ND | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Aggregate risk of bias rating | 16/20 (80%) | 17/20 (85%) | 17/20 (85%) | 16/20 (80%) | 17/20 (85%) | 13/20 (65%) | 12/20 (60%) | 17/20 (85%) | 17/20 (85%) | 13/20 (65%) | 17/20 (85%) | 17/20 (85%) | 17/20 (85%) | 17/20 (85%) |
Abbreviations: ND—not described; NDis—not disclosed; NS—not stated. Aggregate score: all “No”, “ND” and “Ndis” were added up and subtracted from the number of “Yes” to obtain the aggregate risk of bias.
Characteristics of the included studies.
| Author | Location | Study Period | Study Design | Population | Sample | SD | Prev | Self-Medication Agent | Reasons for Self-Medication | Correlates of Self-Medication | Sources of Information |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhang | Australia | March–April 2020 | Online survey | Adults 18+ | 2217 | 49.8% female | 19.5% | Antibiotics | Prevention of COVID-19; | Younger age; | Not reported |
| Wegbom | Nigeria | June–July 2020 | Online survey | Adults (age not specified) | 461 | 57.1% female | 41.0% | Vitamin C; | Anxiety about COVID-19; | Female gender; | Medical personnel; |
| Quispe-cañari | Peru | 25 May to 3 June 2020 | Online survey | Adults 18+ | 3792 | 54.5% female | 43.8% | Acetaminophen; | Prevention of COVID-19; | Older age; | Not reported |
| Sadio | Togo | 23 April to 8 May 2020 | Survey | Adults 18+; healthcare, air transport, police, road transport, informal sectors | 955 | 28.3% female | 34.2% | Vitamin C; | Prevention of COVID-19; | Female gender; | Not reported |
| Elayeh | Jordan | 26 March to 16 April 2021 | Online survey | Adults | 1179 | 46.4% female | 80.4% | Antibiotics (azithromycin and doxycycline); | Prevention of COVID-19; | Female gender; | Newspapers; |
| Shakeel | India | May 2021 | Online survey | Adults | 920 | 28.6% female | 59.9% | Paracetamol; | Prevention of COVID-19; | Male gender; | Family; |
| Azhar | Pakistan | 2020 (month unspecified) | Online survey | Adults 16–60 years | 290 | 66.3% female | 59.5% | Herbal medicines, sana makhi; | Prevention of COVID-19; | Not reported | Not assessed |
| Annette 2021 | Indonesia | July–December 2020 | Online survey | Adults; mothers 18–49 with school-age children | 610 | 100% female | 75.0% | Antibiotics; | Prevention of COVID-19; | Not reported | Family; |
| de los Ángeles | Ecuador | 2020 (date unspecified) | In-person and online survey | Adults | 829 | 57.8% | 96.2% | Eucalyptus; | Prevention of COVID-19; | Not reported | |
| Heshmatifar | Iran | 2020 | Online survey | Adults; > 60 years | 342 | 55.5% | 56.4% | Analgesics; | Prevention of COVID-19; | Not reported | Not reported |
| Gaviria-Mendoza 2022 | Columbia | June–September 2020 | Survey | Adults | 397 | 58.20% female | 7.40% | Chloroquine; hydroxychloroquine;ivermectin;azithromycin | To prevent COVID-19 | Distrust in health personnel or institutions;fear of being sanctioned or fined for leaving the home | Social network |
| Okoye et al. 2022 | Nigeria | March–April 2021 | Survey | Adults | 638 | 58.60% female | 36% | Ivermectin;azithromycin;vitamin C;chloroquine;zinc | To prevent COVID-19 and treat symptoms | Older age;married;pharmacist;higher annual income | Not assessed |
| Dehghan 2022 | Iran | April–August | Survey | Adults | 782 | 66.60% female | 84% | Nutritional supplements such as vitamin D, vitamin C, multivitamin, and others, including vitamin B6, vitamin B complex, vitamin E, zinc, calcium, iron, omega-3, and folic acid, or a combination of supplements | To prevent the transmission of COVID-19 or to reduce anxiety caused by the COVID-19 pandemic or both | Female gender; place of residence; COVID-19 Screening | Friends |
| Kristoffersen 2022 | Norway, ( | April–June 2020 | Telephone interview and online survey | Adults | 2494 | 49.7% female | Prevention, 3.4% and treatment, 0.2% | Vitamin C ( | To prevent and treat COVID-19 | Not assessed | Not assessed |
Abbreviations: SD—sample distribution; Prev—prevalence.
Figure 2Forest plot for the pooled prevalence of COVID-19-related self-medication [6,11,12,18,19,20,21,22,23,24,25,26,27,28].
Figure 3Medicinal agents used for COVID-19-related self-medication in reviewed studies.
Categories of medicinal agents used for COVID-19-related self-medication.
| Drug Class | Names of Specified Medications in the Studies | |||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotics | Azithromycin | Penicillin | Doxycycline | Ciprofloxacin | Erythromycin | Metronidazole | Levofloxacin | Cephalosporins |
| Antimalarials | Chloroquine/hydroxychloroquine | Quinine | Unspecified antimalarials | |||||
| Analgesics and antipyretics | Ibuprofen | Diclofenac | Acetaminophen | Aspirin | ||||
| Minerals supplements | Calcium | Zinc | Magnesium | Aluminium | Omega-3 fatty acids | Immune boosters | ||
| Cold and allergy preparations | Cough syrups | Lozenges | Nasal solutions | Clove oil | Menthol rub | Expectorants | Unspecified cold and allergy preparations | |
| Corticosteroids | Dexamethasone | Unspecified corticosteroids | ||||||
| Antithrombotics | Aspirin | Enoxaparin | ||||||
| Anthelmintics | Ivermectin | |||||||
| Antihistamines | Famotidine | Unspecified antihistamine | ||||||
| Herbs and natural agents | Ginger | Eucalyptus | Unspecified traditional medicine | Unspecified herbal products | Honey | Sana | Makhi | Propolis |
| Vitamins | Vitamin C | Multivitamins | Vitamin C | Vitamin D | ||||
| Antivirals | Antiretrovirals | |||||||
Figure 4Reasons for self-medication by number of studies.